@article{22ba447763ae4581a62a894ebdf79a45,
title = "Understanding the role of patient preference in the treatment algorithm for chronic low back pain: Results from a survey-based study",
abstract = "Aims: Interventional pain treatments range from injections to established radiofrequency ablation techniques and finally neuromodulation. In addition to safety, efficacy and cost dominance, patient preference for type of treatment is important. Methods: Chronic pain patients (n = 129) completed a preference scale to determine which interventional pain management procedures they would prefer from among radiofrequency ablation, temporary (60-day) peripheral nerve stimulation (PNS), conventional PNS and spinal cord stimulation/dorsal root ganglion stimulation. A second survey (n = 347) specific to assessing the preference for radiofrequency ablation or temporary PNS treatment was completed by patients with low back pain. Results: On the basis of mean rank, temporary PNS percutaneously implanted for up to 60 days was the most preferred treatment compared with the other options presented (p = 0.002). Conclusions: Patient preference should be unbiased and considered as an independent variable for physician discussion in treatment options and future research.",
keywords = "back pain, chronic back pain, low back pain, patient preference, peripheral nerve stimulation, radiofrequency ablation, spinal cord stimulation",
author = "Staats, {Peter S.} and Timothy Deer and Einar Ottestad and Michael Erdek and David Spinner and Amitabh Gulati",
note = "Funding Information: This work was conducted at SPR Therapeutics, OH, USA, and this study was supported by a grant from SPR Therapeutics. This study was funded by SPR Therapeutics, Inc. P Staats serves as a consultant to electroCore, Medtronic, Nalu, Saluda and SPR Therapeutics. A Gulati is a consultant for Flowonix, Medtronic, Nalu, SPR Therapeutics and Bausch Health and serves on the advisory board for AIS. E Ottestad serves as a consultant to Bioness, Ipsen, Nine Continents, SPR Therapeutics and Tulavi. T Deer serves as consultant to Abbott, Axonics, Boston Scientific, Cornerloc, Medtronic, Nalu, Nevro, Saluda and SPR Therapeutics. Funded research: Abbott, Avanos, Boston Scientific, Saluda and SPR Therapeutics. D Spinner is a consultant for Bioness, SPR Therapeutics and Nalu Medical. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript. Publisher Copyright: {\textcopyright} 2021 SPR Therapeutics, Inc.",
year = "2022",
month = apr,
doi = "10.2217/pmt-2021-0011",
language = "English (US)",
volume = "12",
pages = "371--382",
journal = "Pain Management",
issn = "1758-1869",
publisher = "CORE Medical Journals",
number = "3",
}